The use of Senexin A does not distinguish CDK8 and CDK19 activities, as their active sites are identical, but Senexin A treatment can be administered exclusively during infection without prior treatment or selection and did not negatively affect Huh7 cell proliferation at the concentrations used in this study (12–25 μM) (Figure 3A). The gene discussed is CDK19; the disease is infection.